GeneralNeutralBlockonomi · 13h ago5/10
📰
GSK (GSK) Stock Slides 3% Following $10.6B Nuvalent Acquisition Deal
GSK announced a $10.6 billion acquisition of Nuvalent, a move that triggered a 3% decline in GSK stock. The deal brings two late-stage lung cancer therapeutics into GSK's pipeline, with FDA approval anticipated in 2026, representing the company's continued investment in oncology despite immediate market skepticism.